Evidence map›Paper›PMID 29033834›Full record

ArticleFrontiers in pharmacology2017

TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors.

Teagan R Wall, Brandon J Henderson, George Voren, Charles R Wageman, Purnima Deshpande, Bruce N Cohen, Sharon R Grady, Michael J Marks, Daniel Yohannes, Paul J Kenny and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Switchable Regioselective 6-Journal of the American Chemical Society · 2022
    Article
  2. Review
  3. Simulations of Promising Indolizidine-International journal of molecular sciences · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Teagan R WallDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Brandon J HendersonDepartment of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.
George VorenDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Charles R WagemanInstitute of Behavioral Genetics, University of Colorado, Boulder, Boulder, CO, United States.
Purnima DeshpandeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Bruce N CohenDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Sharon R GradyInstitute of Behavioral Genetics, University of Colorado, Boulder, Boulder, CO, United States.
Michael J MarksInstitute of Behavioral Genetics, University of Colorado, Boulder, Boulder, CO, United States.
Daniel YohannesTargacept, Inc., Winston-Salem, NC, United States.
Paul J KennyDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Merouane BencherifTargacept, Inc., Winston-Salem, NC, United States.
Henry A LesterDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
California Institute of Technology · USUniversity of Colorado Boulder · USIcahn School of Medicine at Mount Sinai · USMarshall University · US

Funding

Optimizing Drug-like PropertiesP01DA033622 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI KAMENECKA, THEODORE M, KENNY, PAUL J. · 2012 to 2016
$8.3M
Project 3 University of Colorado, BoulderU19DA019375 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI LESTER, HENRY A. · 2005 to 2014
$8.3M
Studies with Nicotinic Null Mutant MiceP30DA015663 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI MARKS, MICHAEL J · 2003 to 2013
$4.5M
Mechanisms of nicotine reinforcement in miceR01DA020686 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI KENNY, PAUL J. · 2007 to 2016
$3.6M
Expression and Characterization of alpha6beta2beta3 nicotinic receptorsF32DA033721 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HENDERSON, BRANDON JARROD · 2012 to 2014
$150k
NIDA NIH HHS F32 DA033721NIDA NIH HHS P01 DA033622NIDA NIH HHS P30 DA015663NIDA NIH HHS R01 DA020686NIDA NIH HHS U19 DA019375
6 · The paper itself

Abstract

(E)-5-(Pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423) is a novel agonist for nicotinic acetylcholine receptors (nAChRs). We examined its efficacy, affinity, and potency for α6β2

Indexed as

electrophysiologyhexahydroazocineneuroprotectionnicotine addictionnicotinic acetylcholine receptorspyrimidinetransmitter releaseα6β2∗

Identifiers

PMID29033834
PMCPMC5626944
OpenAlexW2760739545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.